Department of Dental Implant Center, Stomatologic Hospital and College, Anhui Medical University, Key Laboratory of Oral Diseases Research of Anhui Province, Hefei 230032, China.
Chief Physician, Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Aging (Albany NY). 2021 Jul 11;13(13):17789-17817. doi: 10.18632/aging.203269.
Chemokines play a significant role in cancer. CXC-motif chemokine ligands (CXCLs) are associated with the tumorigenesis and progression of head and neck squamous cell carcinoma (HNSC); however, their specific functions in the tumor microenvironment remain unclear. Here, we analyzed the molecular networks and transcriptional data of HNSC patients from the Oncomine, GEPIA, String, cBioPortal, Metascape, TISCH, and TIMER databases. To verify immune functions of CXCLs, their expression was analyzed in different immune cell types. To our knowledge, this is the first report on the correlation between CXCL9-12 and 14 expression and advanced tumor stage. CXCL2, 3, 8, 10, 13, and 16 were remarkably related to tumor immunity. Kaplan-Meier and TIMER survival analyses revealed that high expression of CXCL1, 2, 4, and 6-8 is correlated with low survival in HNSC patients, whereas high expression of CXCL9, 10, 13, 14, and 17 predicts high survival. Only CXCL13 and 14 were associated with overall survival in human papilloma virus (HPV)-negative patients. Single-cell datasets confirmed that CXCLs are associated with HNSC-related immune cells. Thus, CXCL1-6, 8-10, 12-14, and 17 could be prognostic targets for HNSC, and CXCL13 and 14 could be novel biomarkers of HPV-negative HNSC.
趋化因子在癌症中发挥着重要作用。CXC 基序趋化因子配体(CXCLs)与头颈部鳞状细胞癌(HNSC)的发生和进展有关;然而,它们在肿瘤微环境中的具体功能仍不清楚。在这里,我们分析了来自 Oncomine、GEPIA、String、cBioPortal、Metascape、TISCH 和 TIMER 数据库的 HNSC 患者的分子网络和转录数据。为了验证 CXCLs 的免疫功能,我们分析了它们在不同免疫细胞类型中的表达。据我们所知,这是第一篇关于 CXCL9-12 和 14 表达与晚期肿瘤分期之间相关性的报告。CXCL2、3、8、10、13 和 16 与肿瘤免疫显著相关。Kaplan-Meier 和 TIMER 生存分析显示,CXCL1、2、4 和 6-8 的高表达与 HNSC 患者的低生存率相关,而 CXCL9、10、13、14 和 17 的高表达预示着高生存率。只有 CXCL13 和 14 与 HPV 阴性患者的总生存率相关。单细胞数据集证实 CXCLs 与 HNSC 相关的免疫细胞有关。因此,CXCL1-6、8-10、12-14 和 17 可能是 HNSC 的预后靶标,而 CXCL13 和 14 可能是 HPV 阴性 HNSC 的新型生物标志物。